Andrew Allen, Gritstone bio CEO (via website)
September 27, 2023 04:01 PM EDTUpdated 04:49 PM
R&D

Grit­stone inks up to $433M con­tract with BAR­DA for 10,000-per­son Covid-19 vac­cine tri­al

Kyle LaHucik

Senior Reporter

Grit­stone bio will get up to $433 mil­lion from the US gov­ern­ment to run a Phase IIb tri­al ear­ly next year test­ing its self-am­pli­fy­ing mR­NA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times